secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001558370-24-009313
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC518 Ph2 PIVOT-HD shows mHTT lowering and clinical trends; FDA lifts partial clinical hold
--------------------------------------------------------------------------------

- PTC518 lowered mHTT in blood by 22% (5mg) and 43% (10mg) at Month 12; similar CSF levels.
- Total Motor Score worsening: 2.0 (5mg), 1.3 (10mg) vs 4.9 for placebo, suggesting slowed progression.
- FDA lifted partial clinical hold on PTC518 program based on PIVOT-HD interim data.
- Company received $250M from Royalty Pharma for first tranche of Evrysdi royalty sale under amended agreement.
- Hopewell lease amended to significantly reduce space and rent; lease no longer considered material.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000155837024009313/0001558370-24-009313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000155837024009313/tmb-20240617x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer